Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer vaccine
Biotech
Ultimovacs lays off 40% in wake of cancer vaccine's phase 2 fail
Ultimovacs previously already hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial.
James Waldron
Apr 17, 2024 8:22am
AACR: Cancer vaccines get a reintroduction
Apr 10, 2024 4:30am
AACR: BioNTech cancer vax spurs immune response 3 years in
Apr 7, 2024 2:00pm
Peter Marks says FDA ready to review novel cancer vaccines
Apr 3, 2024 2:39pm
Gritstone ground down by phase 2 cancer vaccine fail
Apr 2, 2024 5:09am
Sellas jettisons 2 execs while awaiting ph. 3 cancer vax readout
Mar 8, 2024 10:09am